# Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations



### Home | Modify Search

Search Results for Proprietary Name, Active Ingredient or Application Number: 017821



#### Home | Back to Search Results

## Product Details for NDA 017821

### Expand all



#### Home | Back to Product Details

Additional Information about Patents

- Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
- Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
   As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

## Patent and Exclusivity for: N017821



#### Home | Back to Search Results

## Product Details for NDA 017821

#### Expand all

# FLEXERIL (CYCLOBENZAPRINE HYDROCHLORIDE) 5MG \*\*Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons\*\* Marketing Status: Discontinued FLEXERIL (CYCLOBENZAPRINE HYDROCHLORIDE) 10MG \*\*Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons\*\* Marketing Status: Discontinued Active Ingredient: CYCLOBENZAPRINE HYDROCHLORIDE Proprietary Name: FLEXERIL Dosage Form; Route of Administration: TABLET; ORAL Strength: 10MG "Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons\*\* Reference Listed Drug: Yes Reference Standard: No TE Code: Application Number: N017821 Approval Date: Approved Prior to Jan 1, 1982 Applicant Holder Full Name: JANSSEN RESEARCH AND DEVELOPMENT LLC Marketing Status: Discontinued Patent and Exclusivity Information

### Home | Back to Product Details

Additional Information about Patents

- Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
- Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
   As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

## Patent and Exclusivity for: N017821

